Literature DB >> 8641321

Determination of (+)- and (-)-nicardipine concentrations in human serum and their correlation with the antihypertensive effect after oral administration of racemic nicardipine.

T Iwaoka1, N Inotsume, J Inoue, S Naomi, Y Okamoto, S Higuchi, M Nakano, T Umeda.   

Abstract

Serum (+)- and (-)-nicardipine concentrations were determined after oral administration of racemic nicardipine, and the relationship between the concentration of each enantiomer and the percentage change in blood pressure was investigated. Serum concentrations of (+) and (-)-nicardipine were assayed separately by a method combining high-performance liquid chromatography (HPLC) with gas chromatography - mass spectrometry (GS-MS). Linear relationships were found with serum concentrations of 0.25-80 mg x ml(-1) for both enantiomers of nicardipine with correlation coefficients of greater than 0.999. A single oral dose of 40 mg racemic nicardipine was given to 15 patients with essential hypertension. Serum (+)-nicardipine concentration was 2-3 times higher than the concentration of (-)-nicardipine 1, 2, and 3 after drug administration. The logarithmically transformed value of the serum (+)-nicardipine concentration was inversely correlated with the percentage change in systolic blood pressure, the correlation being statistically significant 1 and 2 h after drug administration, and also inversely correlated with the percentage change in diastolic blood pressure 1, 2 and 3 h after drug administration. However, the logarithmically transformed value of serum (-)-nicardipine showed no significant correlations with the percentage change in either systolic or diastolic blood pressure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8641321     DOI: 10.1007/bf00194949

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs.

Authors:  S Higuchi; H Sasaki; Y Shiobara; T Sado
Journal:  Xenobiotica       Date:  1977-08       Impact factor: 1.908

2.  Acute and long-term hypotensive effects and plasma concentrations of nifedipine in patients with essential hypertension.

Authors:  K Aoki; K Sato; Y Kawaguchi; M Yamamoto
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Central and peripheral hypotensive effects of the optical isomers of nicardipine, a dihydropyridine calcium channel antagonist, in rats.

Authors:  A M Brisac; P Champéroux; B Lucet; S Laurent; H Schmitt
Journal:  Eur J Pharmacol       Date:  1988-01-27       Impact factor: 4.432

4.  Vasodilator and hypotensive effects of the optical isomers of nicardipine (YC-93), a new Ca2+-antagonist.

Authors:  T Takenaka; I Miyazaki; M Asano; S Higuchi; H Maeno
Journal:  Jpn J Pharmacol       Date:  1982-08

5.  Determination of (+)- and (-)-nilvadipine in human plasma using chiral stationary-phase liquid chromatography and gas chromatography-mass spectrometry, and a preliminary pharmacokinetic study in humans.

Authors:  Y Tokuma; T Fujiwara; H Noguchi
Journal:  J Pharm Sci       Date:  1987-04       Impact factor: 3.534

6.  Plasma levels of (+)- and (-)-nilvadipine after oral dosing with racemic (+)-nilvadipine in man.

Authors:  Y Tokuma; T Fujiwara; H Noguchi
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1987-08

7.  Comparative effects of felodipine, nitrendipine and nifedipine in healthy subjects: concentration-effect relationships of racemic drugs and enantiomers.

Authors:  P A Soons; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.

Authors:  P A Soons; T M Mulders; E Uchida; H C Schoemaker; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen; N J Christensen; H J Kornerup; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

10.  Stereoselective oxidation and plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man.

Authors:  T Niwa; Y Tokuma; K Nakagawa; H Noguchi; Y Yamazoe; R Kato
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1988-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.